|
gptkbp:instance_of
|
gptkb:monoclonal_antibody
|
|
gptkbp:approves
|
gptkb:Oncology
gptkb:cutaneous_squamous_cell_carcinoma
advanced basal cell carcinoma
|
|
gptkbp:chemical_formula
|
C6420 H9920 N1716 O1984 S44
|
|
gptkbp:clinical_trial
|
Phase 1
Phase 2
Phase 3
improved overall survival
improved progression-free survival
NCT03433113
tolerable safety profile
NCT02721732
NCT02819352
NCT03422063
NCT03422076
|
|
gptkbp:clinical_use
|
oncology
|
|
gptkbp:developed_by
|
gptkb:Regeneron_Pharmaceuticals
|
|
gptkbp:discovery
|
humanized monoclonal antibody technology
|
|
gptkbp:discovery_institution
|
gptkb:Regeneron_Pharmaceuticals
|
|
gptkbp:discovery_year
|
gptkb:2015
|
|
gptkbp:emaapproval_date
|
July 2019
|
|
gptkbp:healthcare
|
September 28, 2018
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Cemiplimab
|
|
gptkbp:indication
|
unresectable or metastatic cutaneous squamous cell carcinoma
advanced basal cell carcinoma
first-line treatment for NSCLC
|
|
gptkbp:injection_type
|
subcutaneous
|
|
gptkbp:invention
|
patented
|
|
gptkbp:knockouts
|
high affinity for PD-1
|
|
gptkbp:marketed_as
|
gptkb:Libtayo
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:Japan
gptkb:United_States
|
|
gptkbp:mechanism_of_action
|
immune checkpoint inhibitor
|
|
gptkbp:related_products
|
gptkb:Atezolizumab
gptkb:Nivolumab
gptkb:Durvalumab
gptkb:Pembrolizumab
|
|
gptkbp:research_areas
|
gptkb:cancer_treatment
gptkb:immunotherapy
|
|
gptkbp:route_of_administration
|
intravenous
|
|
gptkbp:service_frequency
|
every 2 weeks
|
|
gptkbp:side_effect
|
fatigue
nausea
hepatitis
diarrhea
rash
pneumonitis
endocrinopathies
arthralgia
pruritus
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:targets
|
gptkb:PD-1
|
|
gptkbp:weight
|
146 k Da
|
|
gptkbp:bfsParent
|
gptkb:Hoffmann-La_Roche
gptkb:Keytruda
|
|
gptkbp:bfsLayer
|
6
|